BLB&B Advisors LLC Reduces Holdings in Bristol-Myers Squibb (NYSE:BMY)

BLB&B Advisors LLC lowered its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 8.9% during the 4th quarter, Holdings Channel.com reports. The institutional investor owned 23,539 shares of the biopharmaceutical company’s stock after selling 2,294 shares during the period. BLB&B Advisors LLC’s holdings in Bristol-Myers Squibb were worth $1,331,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. AMF Tjanstepension AB raised its holdings in Bristol-Myers Squibb by 6.9% in the third quarter. AMF Tjanstepension AB now owns 610,181 shares of the biopharmaceutical company’s stock worth $31,618,000 after purchasing an additional 39,419 shares in the last quarter. Atomi Financial Group Inc. bought a new position in shares of Bristol-Myers Squibb in the 3rd quarter worth about $371,000. CWM LLC lifted its position in Bristol-Myers Squibb by 7.1% during the 3rd quarter. CWM LLC now owns 581,448 shares of the biopharmaceutical company’s stock valued at $30,084,000 after acquiring an additional 38,761 shares during the period. Wedmont Private Capital grew its holdings in Bristol-Myers Squibb by 14.1% in the third quarter. Wedmont Private Capital now owns 8,095 shares of the biopharmaceutical company’s stock worth $433,000 after purchasing an additional 999 shares during the period. Finally, Sanibel Captiva Trust Company Inc. increased its stake in shares of Bristol-Myers Squibb by 47.1% during the third quarter. Sanibel Captiva Trust Company Inc. now owns 35,320 shares of the biopharmaceutical company’s stock valued at $1,827,000 after purchasing an additional 11,315 shares in the last quarter. 76.41% of the stock is owned by institutional investors.

Bristol-Myers Squibb Trading Down 0.8 %

Shares of NYSE:BMY opened at $56.96 on Friday. The stock’s 50-day simple moving average is $57.61 and its two-hundred day simple moving average is $53.65. The stock has a market capitalization of $115.51 billion, a price-to-earnings ratio of -15.86, a PEG ratio of 2.10 and a beta of 0.45. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.10. The company has a debt-to-equity ratio of 2.83, a quick ratio of 1.09 and a current ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. Analysts expect that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Friday, January 3rd were given a dividend of $0.62 per share. The ex-dividend date was Friday, January 3rd. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. This represents a $2.48 annualized dividend and a yield of 4.35%. Bristol-Myers Squibb’s payout ratio is -69.08%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on BMY. Bank of America reissued a “neutral” rating and issued a $63.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, December 10th. Wolfe Research initiated coverage on Bristol-Myers Squibb in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Morgan Stanley lifted their price target on Bristol-Myers Squibb from $36.00 to $39.00 and gave the stock an “underweight” rating in a research report on Tuesday, November 12th. Sanford C. Bernstein assumed coverage on shares of Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective on the stock. Finally, Cantor Fitzgerald lifted their target price on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a report on Tuesday. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Bristol-Myers Squibb has an average rating of “Hold” and an average target price of $57.86.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.